Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

2008. Revenues under collaborative agreements were $44.6 million for the nine months ended September 30, 2009, compared to $57.2 million for the same period in 2008. The decrease reflects lower cost-sharing payments from Lilly for development expenses for BYETTA and exenatide once weekly.

Selling, general and administrative expenses decreased to $259.7 million for the nine months ended September 30, 2009, from $309.0 million for the same period in 2008. The decrease primarily reflects lower sales force and business infrastructure expenses driven by the Company's reduced cost structure.

Research and development expenses decreased to $176.3 million for the nine months ended September 30, 2009, from $226.1 million for the same period in 2008. The decrease primarily reflects decreased development expenses for exenatide once weekly and the Company's obesity programs following recently completed clinical trials and efficiencies driven by the Company's reduced cost structure. Research and development expenses for the nine months ended September 30, 2008 included an $8.0 million license payment for drug delivery technology. Non-GAAP research and development expenses net of cost-sharing payments decreased to $134.9 million for the quarter ended September 30, 2009 compared to $172.1 million for the same period in 2008.

Collaborative profit sharing was $227.5 million for the nine months ended September 30, 2009, compared to $229.4 million for the same period in 2008.

Non-GAAP operating loss was $41.7 million for the nine months ended September 30, 2009, a 64% improvement over the $117.0 million loss for the same period in 2008. Net loss was $136.0 million, or $0.97 per share for the nine months ended September 30, 2009, compared to $216.7 million, or $1.58 per share, for the same period in 2008. Net loss for the nine months ended September 30, 2008 included a loss on impairment of investments of $14.9 million, or $0.11 p
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Mich., Jan. 9, 2012  Diplomat Specialty Pharmacy, the nation,s ... today it has received limited distribution rights from ... On November 18, 2011, EYLEA ... Drug Administration and is indicated for the treatment ...
... Calif., Jan. 9, 2012 Uptake Medical ® ... C funding round. The round was led by Singapore-based ... Ventures, GBS Venture Partners, WRF Capital, Arboretum Ventures and ... managing partner, will join the Uptake Medical board of ...
Cached Medicine Technology:Diplomat Specialty Pharmacy to Provide Specialty Pharmacy Services for EYLEA™ (aflibercept) Injection 2Uptake Medical Announces Successful Completion of Series C Financing 2
(Date:10/20/2014)... 20, 2014 hc1.com today announced ... cloud solution that enables healthcare organizations of all ... healthcare-specific customer relationship management (“CRM”) solution. , Designed ... needs of the healthcare industry, the hc1 Healthcare ... and patients by combining healthcare CRM, HIPAA-compliant collaboration, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 National Teen Driver ... of the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ... in encouraging parents of teen drivers to talk to their ... road. , Motor vehicle crashes are the leading cause of ... drivers involved in fatal crashes, and 859 (42%) of those ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 Houston ... to present the key elements of his innovative ... professor to plastic surgery residents and faculty at ... , where he, too, was once a medical student. ... the largest private cosmetic plastic surgery practices in Texas, ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... its leadership in the companion fields of stem cell research ... a new Stem Cell and Regenerative Medicine Center. ... (May 17) at a public lecture by famed developmental biologist ... the stage for a critical central entity under which the ...
... set a target of ten years for developing an AIDS ... ,"We have learned in that period of time how formidable ... president for research and development at the International AIDS Vaccine ... increased from $186 million in 1997 to $759 million in ...
... botched up surgeries generally suffer in silence, cough up more money ... mixed results. ,And here comes the news that a ... charging a flat fee that includes 90 days of follow-up treatment. ... come back to the hospital, it would not to send the ...
... effective in preventing vaginal and vulvar tumors, according to a ... Lancet, Dow Jones reports. ,Gardasil in clinical trials ... with strains 16 and 18, which together cause about 70% ... HPV strains 6 and 11, which together with HPV strains ...
... and Child Welfare, Dr. David Parirenyatwa, says that the ... severely compromised the country's health delivery system. ... Health Assembly in Geneva, Switzerland, to join the country ... He calls the sanctions an unacceptable and unjustified ...
... people who are affected by chronic back pain can ... discs , spinal stenosis, and complications from failed back ... chronic back pain is considered unsuitable due to its ... new study led by Dr. David Abejn investigates the ...
Cached Medicine News:Health News:UW Establishes Stem Cell and Regenerative Medicine Center 2Health News:AIDS Vaccine Still a Long Way Off 2Health News:US Hospital Group Offers Warranty on Surgeries 2Health News:US Hospital Group Offers Warranty on Surgeries 3Health News:Sanctions Imposed On Zimbabwe Can Threaten International Health Security 2
... The RX daytona is a fully automated ... in bench top analysers offering many features ... systems. With reusable glass cuvettes, on board ... reagents, the random access analyser can accommodate ...
Inquire...
... SelectSecure Lead System (Model 3830) is the ... lumenless design allows for flexibility and a ... insulation thickness. The SelectSecure lead system utilizes ... the lead in select locations in either ...
... protease secreted by the kidney, plays ... system. The renin-angiotensin system regulates blood ... retention by the kidney. Renin is ... including decreased intravascular volume and decreased ...
Medicine Products: